



## ASX and Media Release

# Progress of CAVATAK™ phase II melanoma trial to be presented at ASCO

**16 May 2013, Sydney, Australia:** Viralytics Limited (ASX:VLA, OTC:VRACY) is pleased to announce that a report on the design and progress of the phase II CAVATAK™ late stage melanoma (CALM) clinical trial has been accepted for a poster presentation at the world's foremost oncology conference. The poster will feature in the "Trials in Progress" section at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4, 2013.

Attendance at ASCO in 2012 exceeded 31,000 from the international oncology community.

The Viralytics poster presentation is entitled:

**Abstract TPS3128: "CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma"**

Dr Robert Andtbacka, lead study investigator from the Huntsman Cancer Institute, Utah, USA, will present the poster on June 3. Dr Andtbacka will provide an overview of the design of the CALM trial and an update on patient recruitment. At present 33 melanoma patients have received intratumoural injections of CAVATAK™ in this phase II study with a target total of 54 evaluable patients.

Following presentation of the poster, it will be made available on the Viralytics website. A copy of the abstract is now available on the ASCO website at:

[http://abstracts2.asco.org/AbstView\\_132\\_110205.html](http://abstracts2.asco.org/AbstView_132_110205.html)

"ASCO is an excellent forum to generate global interest in CAVATAK™. This is the world's most prestigious cancer research meeting and Viralytics is gratified that the poster presentation on the CAVATAK™ phase II CALM study has been accepted," said Dr Malcolm McColl, Chief Executive Officer of Viralytics.

**Enquiries:**  
**Dr Malcolm McColl**  
**02 9988 4000**

**Rudi Michelson**  
**Monsoon Communications**  
**03 9620 3333**

**About Viralytics Ltd:** Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both

For personal use only



local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Subject to regulatory approval the STORM trial will commence at three prominent UK sites later in 2013. Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTC market.

For personal use only